GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (NAS:ACET) » Definitions » Enterprise Value

Adicet Bio (Adicet Bio) Enterprise Value : $9.94 Mil (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Adicet Bio's Enterprise Value is $9.94 Mil. Adicet Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-142.63 Mil. Therefore, Adicet Bio's EV-to-EBIT ratio for today is -0.07.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Adicet Bio's Enterprise Value is $9.94 Mil. Adicet Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-136.54 Mil. Therefore, Adicet Bio's EV-to-EBITDA ratio for today is -0.07.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Adicet Bio's Enterprise Value is $9.94 Mil. Adicet Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Adicet Bio's EV-to-Revenue ratio for today is .


Adicet Bio Enterprise Value Historical Data

The historical data trend for Adicet Bio's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Enterprise Value Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial - 203.49 438.40 147.38 -57.01

Adicet Bio Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 147.38 39.29 -78.17 -102.40 -57.01

Competitive Comparison of Adicet Bio's Enterprise Value

For the Biotechnology subindustry, Adicet Bio's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Enterprise Value falls into.



Adicet Bio Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Adicet Bio's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Adicet Bio's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adicet Bio  (NAS:ACET) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Adicet Bio's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=9.940/-142.634
=-0.07

Adicet Bio's current Enterprise Value is $9.94 Mil.
Adicet Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-142.63 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Adicet Bio's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=9.940/-136.536
=-0.07

Adicet Bio's current Enterprise Value is $9.94 Mil.
Adicet Bio's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-136.54 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Adicet Bio's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9.940/0
=

Adicet Bio's current Enterprise Value is $9.94 Mil.
Adicet Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adicet Bio Enterprise Value Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicet Bio (Adicet Bio) Business Description

Traded in Other Exchanges
Address
200 Clarendon Street, Floor 6, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Executives
Chen Schor director, officer: See Remarks PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Katie Peng director C/O ADICET BIO, INC., 200 BERKELEY STREET, 19TH FLOOR, BOSTON MA 02116
Steve Dubin director
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Don Healey officer: Chief Technology Officer 2635 TECHNOLOGY FOREST BOULEVARD, THE WOODLANDS TX 77381
Blake Aftab officer: Chief Scientific Officer C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6, BOSTON MA 02116
Francesco Galimi officer: Chief Medical Officer 12930 VIA ESPERIA, DEL MAR CA 92014
Aya Jakobovits director 3135 HUTTON DRIVE, BEVERLY HILLS CA 90210
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Bastiano Sanna director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Orbimed Capital Gp V Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611